BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology, oncology and immunology, today announced completion of enrollment for two clinical trials evaluating its ropeginterferon alfa-2b-njft (BESREMi®). The Phase 2b EXCEED-ET trial (NCT05482971), which is evaluating the effectiv.

Tri-Continental Corporation offers exposure to domestic equity securities with a 3.82% yield, lower than peers but higher than American common equity indices. The TY closed-end fund's shares have gained 14.81% over the past five years, underperforming the S&P 500 but outperforming investment-grade bonds. The fund's portfolio primarily consists of common stocks, with an emphasis on high-yielding dividend stocks, and trades at a 12.06% discount to net asset value.

BOSTON--(BUSINESS WIRE)--Tri-Continental Corporation (the “Corporation”) (NYSE: TY) today declared a second quarter ordinary income distribution of $0.2905 per share of Common Stock and $0.6250 per share of Preferred Stock. In addition, the Corporation declared a total long-term capital gain distribution of $0.2878 per share of Common Stock. Distributions on Common Stock will be paid on June 18, 2024 to Common Stockholders of record on June 10, 2024, and dividends on Preferred Stock will be pai.

BOSTON--(BUSINESS WIRE)--The Board of Directors (the Board) of Tri-Continental Corporation (the Corporation) (NYSE: TY) today announced that the Corporation's 94th Annual Meeting of Stockholders will be held on June 25, 2024 (the Meeting) in Minneapolis, MN. The close of business on April 16, 2024 has been fixed by the Corporation's Board as the record date for the determination of Stockholders entitled to notice of, and to vote at, the Meeting or any postponement or adjournment thereof. At the.

BOSTON--(BUSINESS WIRE)--Tri-Continental Corporation (the “Corporation”) (NYSE: TY) today declared a first quarter ordinary income distribution of $0.2560 per share of Common Stock and $0.6250 per share of Preferred Stock. Distributions on Common Stock will be paid on March 19, 2024 to Common Stockholders of record on March 11, 2024, and dividends on Preferred Stock will be paid on April 1, 2024 to Preferred Stockholders of record on March 11, 2024. The ex-dividend date for both the Common Stoc.

Tri-Continental Corporation is a well-managed closed-end fund with strong long-term performance and a sustainable distribution yield. TY is well positioned in the current equity markets, with top holdings in leading growth stocks like Microsoft, Apple, Alphabet, Meta, and Nvidia. TY has consistently delivered impressive returns over the long-term and pays distributions based on earnings, unlike "return of principal" funds.

Tri-Continental Corporation is an attractive closed-end fund selling at a 13% discount. TY is a balanced fund with a focus on long-term capital growth and current income. The fund has a very low expense ratio, uses modest fixed-cost leverage, and is an excellent core holding for investors concerned about market overvaluation.

BOSTON--(BUSINESS WIRE)--Tri-Continental Corporation (the “Corporation”) (NYSE: TY) today declared a third quarter ordinary income distribution of $0.2607 per share of Common Stock and $0.6250 per share of Preferred Stock. Distributions on Common Stock will be paid on September 19, 2023 to Common Stockholders of record on September 11, 2023 and dividends on Preferred Stock will be paid on October 2, 2023 to Preferred Stockholders of record on September 11, 2023. The ex-dividend date for both th.

Multiple risks are swirling simultaneously in U.S. in financial markets and for the world's largest economy as Federal Reserve policy makers prepare to meet in Washington this week. The most crucial question facing investors in the week ahead is whether, after delivering a widely expected quarter-of-a-percentage point interest rate hike on Wednesday, policy makers will show a willingness to hold off on further rate rises in order to assess the damage from their year-long campaign to lower inflation.

The Federal Reserve commissioned a study in 2021 to evaluate, "How Many U.S. Zombie Firms and How Consequential?" In the wake of the largest banking collapses since 2008, this article evaluates which firms may most be at risk from a credit event.